Le Lézard
Classified in: Health
Subject: ACC

Ortho RTi Approves Ernst & Young LLP as New Auditors


KIRKLAND, QC, Dec. 18, 2017 /CNW/ - Ortho Regenerative Technologies Inc. (CSE: ORTH.CN) ("Ortho RTi" or the "Corporation"), an emerging Orthopaedic and Sports Medicine Technology company, today announced that it has changed its auditors from MNP LLP (the "Former Auditors") to Ernst & Young LLP (the "Successor Auditors"). 

At the request of the Corporation, the Former Auditors resigned as auditors of the Corporation effective December 13, 2017. The Board of Directors of the Corporation on the recommendation of the Corporation's Audit Committee has appointed the Successor Auditors as the Corporation's auditors in the place and instead of the Former Auditors until the close of the next annual general meeting of the Corporation. 

There were no reservations or modified opinions in the Former Auditors' audit report for the fiscal year ended January 31, 2017 or any subsequent period, and there are no reportable events, as such term is defined in National Instrument 51-102 ("NI 51-102"), between the Corporation and the Former Auditors.  

The Notice of Change of Auditors, together with the letters from the Former Auditors and the Successor Auditors, has been reviewed by the Corporation 's Audit Committee and Board of Directors. 

The Corporation has filed the change of auditors reporting package on SEDAR in accordance with NI 51-102 on December 18, 2017.   

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair technology to dramatically improve the success rate of sports medicine surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of injuries to tendons, meniscus and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

 

SOURCE Ortho Regenerative Technologies Inc.


These press releases may also interest you

at 13:44
CellFE Inc., a life sciences tools company with a novel microfluidics-based cellular engineering platform, announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting,...

at 13:33
EHN Canada proudly announces a significant regional expansion of EHN Bellwood's legacy in pioneering addiction and mental health treatment centres....

at 13:30
CARBIOS celebrates the groundbreaking of its PET biorecycling plant, a world first, with its partners CARBIOS' first plant is also a world first using revolutionary enzymatic depolymerization technology, marking a major step forward in the...

at 13:25
CBL-514 is the first product to treat cellulite at the raised areas.Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034.CBL-0201EFP...

at 13:15
The Board of Governors of the Canadian Memorial Chiropractic College (CMCC) is delighted to announce the appointment of Dr. Christine Bradaric-Baus as its next President, effective July 1, 2024, following the retirement of President...

at 13:13
Hoag is proud to announce the recruitment of cancer researchers and subspecialized oncologists Monica Mita, M.D., M.Sc., Mh.D.S., and Alain Mita, M.D., M.Sc., to the Hoag Family Cancer Institute....



News published on and distributed by: